Private Advisor Group LLC Raises Stock Holdings in Insulet Co. (NASDAQ:PODD)

Private Advisor Group LLC boosted its stake in Insulet Co. (NASDAQ:PODD) by 131.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 7,387 shares of the medical instruments supplier’s stock after acquiring an additional 4,200 shares during the period. Private Advisor Group LLC’s holdings in Insulet were worth $1,719,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. James Hambro & Partners LLP acquired a new position in Insulet in the 3rd quarter valued at about $213,000. Revolve Wealth Partners LLC acquired a new position in Insulet in the 3rd quarter valued at about $368,000. Chicago Capital LLC grew its position in Insulet by 3.4% in the 3rd quarter. Chicago Capital LLC now owns 168,434 shares of the medical instruments supplier’s stock valued at $39,203,000 after acquiring an additional 5,557 shares in the last quarter. Raymond James & Associates grew its position in Insulet by 3.8% in the 3rd quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock valued at $8,718,000 after acquiring an additional 1,367 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Barclays lifted their target price on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. UBS Group upped their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Citigroup upped their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $242.29.

Insulet Stock Performance

Shares of Insulet stock opened at $230.58 on Thursday. The firm has a market capitalization of $16.17 billion, a P/E ratio of 41.92, a P/E/G ratio of 4.36 and a beta of 1.21. Insulet Co. has a 52 week low of $128.68 and a 52 week high of $243.98. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The firm’s 50 day moving average is $225.17 and its two-hundred day moving average is $200.56.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.38 earnings per share. Research analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.